Previous 10 | Next 10 |
WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, announced today that industry and infectiou...
WALTHAM, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, announced today that following its Annual M...
Gainers:Scholar Rock Holding (SRRK) +6%. Science 37 Holdings (SNCE) +6%. Arcimoto (FUV) +5%. Hyzon Motors (HYZN) +4%. SoundHound (SOUN) +4%. Losers: Guardant Health (GH) -5%. CymaBay Therapeutics (CBAY) -5%. Polestar Automotive Holding (PSNY) -5%. Adagio Therapeutics, (...
Gainers: bluebird (BLUE) +73%. Canopy Growth Corporation (CGC) +10%. Astra Space (ASTR) +5%. Adagio Therapeutics (ADGI) +5%. GDS Holdings Limited (GDS) +5%. Losers: RISE Education Cayman (REDU) -11%. Fulcrum Therapeutics (FULC) -7%. View (VIEW) -5%. Kezar Life Sciences (KZR) -...
Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...
Adagio Therapeutics press release (NASDAQ:ADGI): Q1 GAAP EPS of -$0.93 misses by $0.21. Cash Position: Cash and cash equivalents were $532.2 million as of March 31, 2022. For further details see: Adagio Therapeutics GAAP EPS of -$0.93 misses by $0.21
$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be Presented at ASM Annual Meeting WALTHAM, Mass., May 13, 2022 (GLOBE NEWSWIRE) -...
Adagio Therapeutics (NASDAQ:ADGI) said it was pausing the submission of an emergency use authorization (EUA) request for adintrevimab (ADG20) with the U.S. Food and Drug Administration (FDA) after the drug was seen to show a lack of neutralizing activity against the Omicro...
WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, recently announced positive preliminary cl...
Volatility remains the dominant factor across the equities market, with interest rates rising and growth stocks well underwater so far in 2022. Ground zero for this correction is among “long duration assets”, which includes growth stocks with big hypothetical cash flows down the...
News, Short Squeeze, Breakout and More Instantly...
Adagio Therapeutics Inc. Company Name:
ADGI Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in ...
Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses Invivyd’s new data is...
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Heal...